IDH2 and acute myeloid leukemia: Currently, the clinical benefit of adding enasidenib to induction, consolidation and maintenance therapy for patients with newly diagnosed IDH2 mutant AML is under further evaluation in randomized phase 3 trials (NCT03839771, NCT02577406) (Table 1).